March 2020 Clinical Watch Newsletter

April 29, 2020

In this issue of Clinical Watch, we highlight aspects of Medicaid programs that are affected COVID-19 and suggest prior authorization criteria for a new lipid-lowering drug. Lastly, we review claims data for psychotropic polypharmacy in children.

For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.

Previous Flipbook
April 2020 Clinical Watch Newsletter
April 2020 Clinical Watch Newsletter

In this issue of Clinical Watch, we highlight the NIH Panel recommendations regarding medications associate...

Next Article
Overcoming Payer Barriers through  the Three Pillars of Hub Onboarding: Rate, Time, Duration
Overcoming Payer Barriers through the Three Pillars of Hub Onboarding: Rate, Time, Duration

Pharmaceutical manufacturers and payers are often at odds over pricing and barriers to new medication acces...